Index

Legal cases and publications referred to in the text are in *italics*.

*A & M Records Inc. v Napster* 231, 233, 234, 236, 237, 251, 253

AAAI 174

abolition of patent system negative economic effects on international commercial relations 21

academic institutions biomedical research and development 123–4 commercial development of discoveries made with federal funds 141–2 incentives and rights for innovation 139, 149 interaction with government and private sectors 118, 121, 126, 127–9, 130–33, 142, 143, 155, 156 licensing income 130 technology transfer 142, 143, 146 offices 139, 141–2

Accelerating Access to AIDS drugs Initiative (AAAI) 174

access to medicines 28, 29, 170–71, 173, 174, 175, 183 partnerships with patent holders 175, 183 ageing societies 162, 163 Aghion, P. 106 agriculture competition law 345, 353 European regulation 352–3, 359 see also geographical indications

*Aimster* 253

Arnst, C. 165–6

Attaran, A. 172, 173 Ayres, I. 258

Bagwell, K. 103 Barro, R. 106

Bayh-Doyle Act (1980) 122, 139, 142, 143, 144, 146–7, 149, 153 Benkler, Y. 255 Berkowitz, L. 111 Berkowitz, R. 177, 178 Berne Convention (1886) 245, 259 Bernheim, D. 103 Bhagat, S. 111 bilateral trade agreements 30, 31, 72–3, 307, 320, 325 see also geographical indications biomedical research and development 118 academic institutions, role of 123–4 government role 119, 125, 126 basic research and development 119, 120 creation of framework to encourage research 120–22, 123 technology transfer 140–41 interaction of academic, government and private sectors 118, 121, 126, 127–9, 131, 133 examples of 131–3 license agreements 118–19 private-sector organizations clinical trials 124–5 location of facilities near to academic institutions 123–4 product development 124, 125 role of 124, 125 Bishop, E. 20 Black, F. 93 Boyle, J. 245 Breyer, Justice 231, 239, 240, 260 Buchanan, J. 104

*C.B.S. Songs Ltd. & Ors v Amstrad Consumer Electronics Plc. & Anor.* 235
Index

Chamberlin, E. 8
Chiron Corporation v Organon Teknika 197
Cockburn, I. 126
Colson, T. 111
competition law 213, 214, 226, 227
government markets 345, 353
geographical indications 351, 352, 354, 355, 356
prohibited agreements 215
compulsory licenses 171, 179, 180, 181, 182, 183, 218, 220, 223, 226, 227
Conrad, J. 12, 13
Consten and Grundig v Commission 214
customer protection laws
geographic origin of goods 348
labelling 320, 348
unfair competition 348
see also geographical indications
customer substitutes 251
Cooperative Research and Development Agreements (CRADAs) 122
Copyright Act (1976) 270
copyright law 160–61, 247, 268, 269
access control 278, 279, 280, 281, 282, 284
conflict with freedom of information 281, 282, 283
communication rights 271, 272, 275, 276
customer substitutes 251
contributory or secondary infringement 259
copy protection devices 251
developing countries
impact on 29, 30
future issues 284–5
global definition of the standard of copyright 285
inducement of infringement 237–8
internet regulation 280–83
justifications for 232, 240, 241
balance between property as capital reward and the public domain 241, 242, 243
ensuring fair and equal shares for all based on ethical grounds 243–4

music industry 244, 245, 246–7
new business models 251, 252, 253
public domain 269–70, 283
human rights 284
reproduction rights 271, 272, 273–5
shared monopolies
effect on competition 253–5
stakeholders 232
 corporative 249–50
multilevel-creator 250–51
single-creator 249

 technological measures 276, 277, 282, 283
technology 230, 231, 245
as driving force of copyright law 258, 259, 260
example legal force of copyright law 232–40
see also file-sharing technology
counterfeiting see violations of intellectual property rights
CRADAs 122
data protection
deficiencies in 63
de Bouftler, S. 3, 4
Deardorff, A. 38
designation of origin 300
definition of 299
protected designations of origin 300, 313, 347
see also geographical indications
developing countries
copyright
problems of 29, 30
foreign direct investment inflows 48, 49
health care problems 163
impact of intellectual property rights 5, 20–21
imports of goods and services 48
perspectives on the importance of intellectual property rights 47
technology transfer 57, 58, 59
acceptance of 39–40
adoption of model laws 24
implementation 24, 25
pressure to comply with 24
violations of intellectual property rights 65, 66, 67

disease
  cost of 166
  prevalence of 163

Doha Declaration 41–2, 179, 180–81, 183

downstream markets 256, 257

Drahos, P. 27


Druker, B. 132

DSM’s Patent 197

EC see European Commission

economic development
  relationship with intellectual property rights 18, 19, 20, 21, 22, 23, 44, 45

Economist 3

Eisenberg, R. 143

enforcement of intellectual property rights 69, 70
  costs of 38
  dispute settlement mechanisms 74–5

EU
  guidebook 76
  institutional cooperation within
    76–7
  outside EU borders 70
  responsibility of individual Member States 69
  strategy 70–77

identification of priority countries 72

joint initiatives 73

multilateral and bilateral agreements 72–3

obstacles to 67–8

organizations’ strategies 114

political dialogue 73

positive steps towards 68–9

public awareness-raising 75, 76

public–private partnerships 75

technical cooperation 74

see also violations of intellectual property rights

essential medicines 172

access to 170–71, 173, 174

partnerships with patent-holders 175, 183

extent of patenting in developing countries 172, 173, 183

prices of patented medicines 183

European Commission (EC) 63

abuse of a dominant market position 217, 223, 224

refusal to licence 218, 219, 220, 221, 222, 223, 227

Article 81 215, 225

Article 82 217, 226, 227

competition law 214, 226, 227

impact on intellectual property rights 213, 214

prohibited agreements 215

innovation, encouragement of 224, 225, 226, 227

negative sentiment about intellectual property rights 227

technology licensing 215, 216

Technology Transfer Block Exemption Regulation (TTBER) 215–16, 224, 225, 226

Executive Orders 12591 and 12618 (1987) 151

existence/exercise distinction 213–14

Fahey, L. 111

FDI see foreign direct investment


Field, B. 104

File-sharing technology 233–5, 236–7, 238, 239, 240, 246–7, 251, 252, 253, 255

benefits of 255, 256, 257

stakeholders 259–60

Finger, J. 41

Fink, C. 53

Firestone, O. 19

food security 26, 27, 28

Forbes 161

foreign direct investment (FDI)

  impact of intellectual property rights 23, 38, 49, 50, 51, 52, 53, 54, 58, 59

inflows to developing countries 48, 49

technology transfer, role in 48–9

free-rider problem 106
gene patents 188, 205, 206
claims to genes 188, 189, 190
criticisms of 203–4
industrial applicability 200, 201, 202, 203
inventive step
   Europe 194–7
   United States 198, 199
products of nature, as
   Europe 191, 192
   United States 193, 194
public policy concerns 199–200
utility, lack of 200, 201, 202, 203
generics companies
access to drugs 145
entry into developing countries’ markets 173, 174
prices of copy drugs 173, 174, 175
   United States 194–7
   Europe 191, 192
   United States 193, 194
utility, lack of 200, 201, 202, 203
Genetech Inc’s Patent 192, 195, 196, 197
genomics 133
   collaboration of government, academia and industry 133
geographical coverage of patent system 38
   transferring wealth from the poor to the rich 39
geographical indications (GIs) 8, 293, 294, 295, 305, 347
   anti-competitive nature of 356, 358, 359, 360
   authenticity of standards 350, 351
   barrier to market entry 298
   beneficiaries of 301, 302
   bilateral and regional agreements 308, 335, 338
   conflicting EU and US obligations 315
   boundaries 351, 356, 357
   collective nature of the protection 351
   competition law
   interface with 351, 352, 354, 355, 356
   consortia administering of 354, 355, 356
   definition of 293, 300
   developing countries 301, 302
   development and promotion of rural society, role in 298–9
divergent food cultures
   problem of 358
   economic impact of 297
EU bilateral agreements 314
   accordance of automatic protection 315, 316
   comparative analysis of 321–4
   definition of geographical indications 321
   elimination of TRIPS exceptions 316, 317, 322, 337
   homonymous geographical indications 317
   level and means of protection 315, 321, 336
   mutual recognition 324, 337, 338
   objectives of 314, 335
   relationship with trademark protection 318, 323–4
   scope of 337
   structure of 314–15
   traditional expressions 318, 319, 320, 323
EU system for the protection of 299, 300, 301, 312, 313
higher value markets
   restriction of 359
history of 295–7
inappropriate registrations 356, 357
market definitions 355
migration of products 349–50, 357
multilateral register 295, 307
problems of 348, 349
protected geographical indications 300, 313, 347
   shared character of 309–10
source of information for consumers 297
traditional knowledge, protection of 302
   adoption and implementation of standards 306
   continued and similar use of GIs 350
   definition 293, 309, 310
   exceptions 311, 312
   levels of protection 310–11
   scope of protection 310
US regional and bilateral agreements 325, 326, 327
comparative analysis of 333–4
definition and scope 327–8, 333, 337
legal means of protection 328–9, 333, 335–6
mutual protection clauses 331, 332, 334, 338
objectives of 335
procedural features 331, 334
relationship with trademarks 329, 330, 334
TRIPS exceptions 330, 331, 333, 337
violations of 63
wines and spirits 294, 311, 312
see also designation of origin
Georgia-Pacific v U.S. Plywood-Champion Papers Inc. 86
Gillespie–White, L. 173
Ginsburg, Justice 239, 260
Gleevec 132
government
biomedical research and development 119–23, 125, 126, 140–41
interaction with academic and private sectors 118, 121, 126, 127–9, 131–3
provision of intellectual property protection 133, 134
sponsored research
policy issues 143–4
title to inventions 144–5, 149
technology transfer 140–41
Greater Access to Affordable Pharmaceuticals Act (GAAP) 145
Grossman, G. 33, 106
Hall, B. 111
Hansen, F. 111
Hay, J. 165
health care
financing of 164
Helpman, E. 106
Henderson, R. 126
Hoffman, Lord 189, 206
Howard Florey Instituteel Relaxin 191, 199, 201
Howitt, P. 106
Hume, D. 242
ICI and CSC v Commission
(Commercial Solvents case) 218–19, 224
ICOS Corporation 192, 202
imatinib mesylate 131–2
imitation of ideas
disincentive to innovate 106
implementation costs of IPR agreements 47
IMS Health v NDC Health 221, 222, 223, 226, 254
In re Bell 198
In re Deuel 198
In re Wallach 199
incentive to disclose secrets 3–4
industrial significance of patent protection 19
innovation subsidy policy 107
innovative firms 109, 111
Intellectual Property Institute (IPI) 204
intellectual property rights (IPRs)
forms of 362–3
framework for studying 361, 362, 363
history of 363
impact of 361
internet
regulation of 279, 280
copyright 280–83
IPRs see intellectual property rights
Jones, C. 45, 106
Kazaa 236
see also file-sharing technology
Kearney, A. 54
Khan, A. 7
Killinger, S. 103
Kirin-Amgen Inc and others v Transkaryotic Therapies Inc and others 188, 192, 194, 195, 206
Kline, D. 111
knowledge
excludability of, 106–7
investments in 109
high fixed costs of production 106
low marginal costs of production 106
non-rival nature of 106, 107
product life-cycle curve 109, 110
knowledge-based growth (KBG) 105, 106, 107
patents as dominant policy instrument 108
‘knowledge commons’ 143
Kortum, S. 111
Lamberton, D. 20
Lamy, P. 173
Lang, J. 111
Lanjouw, J. 111, 114
Laramie, A. 104
large organizations
long-term patent strategies 111, 112, 113
patent enforcement strategies 114
resources available for patent applications 112–13
timing of patent filings 113–14
Lee, J.-Y. 53
Lerner, J. 111, 114
Lessig, L. 245
licensing 54–5, 56, 57, 58, 59, 154, 215, 216
academic institutions
licensing income 130
between private companies 129, 130
biomedical research and development 118–19
compulsory licenses 171, 179, 180, 181, 182, 183, 218, 220, 223, 226, 227
provisions in license agreements 127, 154
royalty payments 128, 129
technology transfer 54, 55, 56, 127, 128, 129, 133
valuations 84
Lippoldt, D. 44, 46, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57
Litman, J. 255, 256
Llewellyn, D. 19
local reputations 296
see also geographical indications
Locke, J. 240, 241, 242, 243

Macfie, R. 3
Machlup, F. 2, 3, 4, 5, 6, 19, 363
Macleod, H. 3
Mair, D. 104
Mandeville, T. 20
Mansfield, E. 19, 53, 88
market power 217–18
Maskus, K. 44, 55, 56
material transfer agreements (MTAs) 154–5
reach-through provisions 155
Matthews, D. 111
McCain, J. 145
medical technology
access to 165
Merges, R. 111, 112
Michelangelo, B. 249
Microsoft 223–4, 226, 227, 257–8
Mill, J. 168
monopolies 1, 175
Monsanto Canada, Inc. v Schmeiser 26–7
Moran, W. 299
Murtha, E. 81
music industry
copyright law 244, 245
P2P services 246–7
technological protection measures 246
new technologies 244, 245, 251, 252, 253
Music Publishers Association 259
Nalebuff, B. 258
National Academies Press 198
National Competitiveness Technology Transfer Act (1989) 152
National Institutes of Health (NIH) 153
grants 155–6
natural property right in ideas 2–3
Nelson, R. 112
new businesss models 251, 252, 253
NIH see National Institutes of Health
Nogues, J. 41
Nowell, P. 131
Nunnenkamp, P. 53
OECD 45, 49, 54, 298
Olewiler, N. 104
Omnibus Trade and Competitiveness Act (1988) 151
Organization for Economic Co-operation and Development (OECD) 45, 49, 54, 298
organized innovation 6–7
Orphan Drug Act (1983) 161
P2P technology see file-sharing technology
paclitaxel 132
Palda, F. 104
parallel importation 171, 181, 182
counterfeit and substandard drugs 181
Park, W. 44, 46, 49, 50, 51, 52, 53, 54, 55, 56, 57
Parke-Davis v HK Mulford 194
patents 153, 154
applications 112
resources available for 112–13
as charge for knowledge 36
claims 153
dissemination of information 107–8
drivers for 111, 112
exception from monopolies 1
historical debates over patent protection 2, 3, 4, 5, 6
incentives to innovate 107–8
infringements of 63
need for
when inventions cannot be kept secret 34–5
organizations’ strategies 111, 112, 113
social impacts of 35, 36, 38
specification 153
terms 37–8
timing of patent filings 113, 114
tradeoff between public and private benefit 160
PDOs 300, 313, 347
Pharmaceutical industry
extent of research and development 165
global differential pricing systems 182
incremental innovation 176, 177
intellectual property rights 159–60, 164, 165, 166, 167, 168
data protection 161
impact on prices in developing countries 177–8, 183
orphan drugs 161–2
patent life 177
patent term extension 161
proposed global agreement 167
monopoly pricing power 175, 176, 177, 183
pharmaceutical products
financial burden borne by private sector 163–4
financing the development of 42
free-riding countries 167
therapeutic competition 176, 177, 183
Philips v Ingman 220
Pickering, F. 111
Pioneer Hi-Bred International Inc. v J.E.M. Ag Supply Inc. 26
piracy see violations of intellectual property rights
Plant, A. 4, 8
plant variety protection 26, 27, 28
Polanyi, M. 4
pricing 161
Primo Braga, C. 53
private goods 36
private property rights 36
private sector
biomedical research and development 123–5, 126, 127
interaction with academic and government sectors 118, 121, 126, 127–9, 131–3, 142, 143
licensing between companies 129, 130
source of patented technologies to academic institutions 131
sponsorship of research 130–31, 155, 156
protected designations of origin (PDOs) 300, 313, 347
protected geographical indications (PGIs) 300, 313, 347
Prusak, L. 111
public goods 36
financing the production of 36–7
governmental provision of 37

Recording Indus. Association of America, Inc. v Diamond Multimedia Systems Inc. 233
regional trade agreements (RTAs) 47, 307, 320, 325
see also geographical indications
Ricardo, J. 3
rights holders
importance of intellectual property rights 45, 46
Rivette, K. 111
Roberts, K. 104
Rogers, J. 4
Romer, P. 106
Romer, T. 104
Rothschild, R. 111
Rousseau, J.-J. 4
Rozek, R. 177, 178
RTAs see regional trade agreements
RTE and ITP v Commission (Magill case) 219–20, 222, 223, 224, 226, 254

Sala-i-Martin, X. 106
scale neutrality of intellectual property policy instruments 103, 104, 105, 114–15
drivers for patenting intellectual assets 111, 112
patent enforcement strategies 114
resources available for patent applications 112, 113
timing of patent filings 113, 114
Schankerman, M. 111
Schechter, F. 8
Scholes, M. 93
Schumer, C. 144, 145
Schwartz, M. 88
secondary markets 256, 257
Securities Data Corporation 56
Shapiro, C. 33
Silbertson, Z. 19
Small Business Innovation Development Act (1982) 149
small organizations
patent enforcement strategies 114
resources available for patent applications 113
short-term patent strategies 112
timing of patent filings 113
Smarzynska, B. 53
Smith, A. 354
Smith, M. 111
social contract 4
social progress 3
Somaya, D. 114
Sony Corp. v Universal Studios Inc. 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 257, 259
Space-shifting activities 233
Spatz, J. 53
sponsored research 130–31, 143, 144, 145, 149, 155, 156
stakeholders 232, 248
corporate 249–50
multilevel-creator 250–51
primary 248
secondary 248
single-creator 249
Statute of Anne (1710) 245
Statute of Monopolies 1
Stevenson–Wylder Technology Innovation Act (1980) 139, 149
Sunday Telegraph 356
survival rates 165, 166
Tabellini, G. 103
targeted treatment 166
Taxol 132
Taylor, C. 19
technical designs
infringements of 63
technology
copyright law 230, 231
as driving force of 258, 259, 260
equivalent cases 232–40
time and 258, 259
see also technology transfer
technology transfer 21, 39, 146
academic institutions 142, 143, 146
developing countries
influence of intellectual property rights 57, 58, 59
need for complementary conditions 58–9
foreign direct investment, role of 48–9
government sector 140–41
government sponsored research policy issues 143–4
title to inventions 144–5, 149
interaction of academic and private sector 126–7, 142, 143
legislation 149–52
licensing 54, 55, 56, 127, 128, 129, 133
market forces 133, 134
offices 139, 141–2
trade as a vehicle for 47, 48
Teece, D. 109, 111
theft of intellectual property concern of businesses 54
Thomas, Judge 230
Tiercé Ladbroke v Commission 221, 223
time-shifting activities 232, 235
timing of a patent filing 113–14
Tizzano, Advocate General 222
Toole, A. 131
trade
influence of intellectual property rights 49, 50, 51, 53, 58, 59
trade-related aspects of intellectual property rights (TRIPS) agreement 5–6, 17, 18, 40, 41, 46–7, 178, 348
amendments to 41, 42
beneficiaries of 22
compulsory licenses 179, 180
copyright 30
counterfeit medicines 180
countries’ differing stances 305
developing countries acceptance of 39–40
adoption of model laws 24
implementation 24, 25
pressure to comply 24
enforcement of intellectual property rights 72, 73
expenses of 41
geographical indications 293, 294, 295, 305, 308, 318
adoption and implementation of standards 306
continued and similar use of GIs 350
definition of 293, 309, 310
EU elimination of exceptions 316, 317, 322, 337
exceptions 311, 312
levels of protection 310–11
multilateral register 295, 307
scope of protection 310
wines and spirits 294, 311, 312
impact on access to medicines and public health 178–9, 183
institutional costs of compliance 25–6
review agenda 22, 25
technology transfer objectives 21
traditional expressions 319, 320
transfer of wealth from poor to rich 33, 39
see also Doha Declaration
Trademark Clarification Act (1984) 150
trademarks 8, 160
violations of 63
see also geographical indications
traditional expressions 318, 319, 320, 323
traditional knowledge 302
Trajtenberg, M. 111
TRIPS agreement see trade–related aspects of intellectual property rights agreement
UK Commission on Intellectual Property Rights 23
United Nations Conference on Trade and Development (UNCTAD) 5, 19, 25
United States access to generic drugs 145
bilateral and regional agreements 320, 325
preference for 30, 31
government funding for science and technology 140
state-sponsored agricultural certification programmes 346
see also geographical indications

Universal City Studios v Reimerdes 278

universities see academic institutions
US Patent and Trademark Office 346

valuation of intellectual property 67, 81, 83, 99
accounting standards, compliance with 85
acquisitions 84
bankruptcy proceedings 86–7
business decisions 83–4
consistency in valuations 87
cost approach 82
divestitures 84
holding of patents 84
importance of 111
income approach 81, 83, 87–8, 99
discounted cash flow (DCF) method 81, 88–9, 90, 97, 98, 99
real option method 81, 89, 91–7, 99
licensing transactions 84
litigation 86
market approach 82–3
patents as a proxy for 111
spin-offs 84
tax regulations, compliance with 85, 86
venture capital financing 85
Vernon, R. 4, 5
violations of intellectual property rights 63
criminal organizations, involvement of 65
developed countries, effect on 64–5
developing countries, effect on 65, 66, 67
health and consumer protection 64–5
impact on trade 17, 18, 62
need for comprehensive policy to tackle 66, 67
tax revenues, effect on 65
types of 63
see also enforcement of intellectual property rights

Volvo v Veng 219, 220
von Justi, J. 168
Wagner, S. 88
wealthier countries
impact of intellectual property rights 47
Weidenbaum, M. 103
Wertheimer, A. 176
WHO 164, 171, 172, 174–5
WIPO see World Intellectual Property Organization
Wolowski, L. 4
World Health Organization (WHO) 164, 171, 172, 174–5
World Intellectual Property Organization (WIPO) 18, 19
ternational IPR agreements 46, 246
World Trade Organization (WTO) 45, 46, 47, 180, 183
developing countries’ view of 33
see also trade-related aspects of intellectual property rights agreement

Zahra, S. 111